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Thickness and Cardiovascular
Disease Risk PredictionThe American College of Cardiology Foundation (ACCF)/
American Heart Association (AHA) welcomes letters to inform
its ongoing work and encourages such correspondence about
its guidelines. Because the ACCF/AHA guideline development
process is rigorous and involves several layers of review by the
writing committee, external peer reviewers, and participating or-
ganizations in the document, the ACCF/AHA cannot respond to
each issue raised after a guideline has been published. The infor-
mation, however, is forwarded to the Writing Committee chair and
oversight Task Force for review. If any issue is deemed by the
ACCF/AHA to affect patient safety, it will be considered imme-
diately. Otherwise, the information will be considered during the
next update or revision of the guideline.The American College of Cardiology
http://dx.doi.org/10.1016/j.jacc.2014.02.526Beneﬁts of Statins in
Healthy Elderly Subjects
What Is the Number Needed to Treat?I read with interest the paper by Savarese et al. (1) reporting the
results of a meta-analysis of the beneﬁts of statins in elderlysubjects without established cardiovascular (CV) disease. One of
the biggest questions facing clinical cardiology today is the deci-
sion regarding which individuals to treat with statins in primary
prevention. Because statins are not without adverse effects, we
have to be sure that the risk of harm does not outweigh the pre-
sumed beneﬁts.
In their meta-analysis, Savarese et al. (1) came to the conclusion
that statins signiﬁcantly reduce the incidence of myocardial
infarction (MI) and stroke but do not signiﬁcantly prolong survival
in the short-term. They believe their meta-analysis provides “ﬁrst-
time evidence that the beneﬁts of statins on major CV events ex-
tends to people 65 years without CV disease.”
MI occurred in 2.7% of subjects allocated to receive statins
compared with 3.9% of those receiving placebo during a mean
follow-up of 3.5 years. This ﬁnding corresponds to a relative risk
reduction of 39.4%. Stroke was reported in 2.1% of subjects ran-
domized to receive statins compared with 2.8% receiving placebo
during the same mean follow-up period. This ﬁnding corresponds
to a relative risk reduction of 23.8%.
The authors calculated that 24 patients needed to be treated for
1 year to prevent 1 MI and that 42 patients needed to be treated for
1 year to prevent 1 stroke. The authors repeat these numbers in the
ﬁnal section of the paper, where cost/beneﬁt evaluation of statin
treatment in elderly subjects is discussed.
It appears that the authors have made an erroneous calculation.
The annual MI rate was 1.1%, and the annual rate of stroke was
0.8% in patients allocated to receive placebo. Considering a relative
risk reduction of 39.4% and 23.8%, respectively, the absolute risk
reduction (ARR) for 1 year is approximately 0.43% for MI and
0.19% for stroke. The number needed to treat (NNT) is the inverse
of the ARR: NNT ¼ 100/ARR.
By using data from the paper, I have calculated that the
NNT for 1 year to prevent 1 MI and 1 stroke, respectively, may be
approximately 10 times higher than that reported by Savarese et al.
(1), given that NNT is constant over time. In my opinion, the most
appropriate approach would have been to report the NNT for the
mean follow-up of 3.5 years, which would have been approximately
83 to prevent 1 MI and 142 to prevent 1 stroke. This is the
approach most commonly used in similar studies.
The NNT is very important when assessing the efﬁcacy of
statin therapy. It is therefore essential that the authors do a recal-
culation of their data and report the correct NNT numbers. They
may also have to reconsider the main conclusions of their meta-
analysis.*Axel F. Sigurdsson, MD
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